USA - NASDAQ:RPID - US75340L1044 - Common Stock
The current stock price of RPID is 2.87 USD. In the past month the price decreased by -17.05%. In the past year, price increased by 160.91%.
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| TMO | THERMO FISHER SCIENTIFIC INC | 24.92 | 210.82B | ||
| DHR | DANAHER CORP | 27.76 | 153.24B | ||
| BRKRP | BRUKER CORP - BRKR 6 3/8 09/01/28 | 143.51 | 46.81B | ||
| A | AGILENT TECHNOLOGIES INC | 26.28 | 40.60B | ||
| IQV | IQVIA HOLDINGS INC | 18.73 | 37.03B | ||
| MTD | METTLER-TOLEDO INTERNATIONAL | 34.09 | 28.72B | ||
| WAT | WATERS CORP | 28.08 | 20.44B | ||
| WST | WEST PHARMACEUTICAL SERVICES | 40.29 | 20.48B | ||
| MEDP | MEDPACE HOLDINGS INC | 40.88 | 16.42B | ||
| TEM | TEMPUS AI INC | N/A | 15.43B | ||
| ILMN | ILLUMINA INC | 22.84 | 14.61B | ||
| ICLR | ICON PLC | 12.58 | 12.91B |
Rapid Micro Biosystems, Inc. is a life sciences technology company. The company is headquartered in Lexington, Massachusetts and currently employs 163 full-time employees. The company went IPO on 2021-07-15. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. The company offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
RAPID MICRO BIOSYSTEMS INC-A
25 Hartwell Avenue
Lexington MASSACHUSETTS US
CEO: Robert Spignesi
Employees: 163
Phone: 19783493200
Rapid Micro Biosystems, Inc. is a life sciences technology company. The company is headquartered in Lexington, Massachusetts and currently employs 163 full-time employees. The company went IPO on 2021-07-15. Its flagship Growth Direct system automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in pharmaceutical manufacturing operations. The company offers four specific applications for testing of microbial contamination: Environmental Monitoring, which tests the manufacturing environment, including circulating air, exposed surfaces, and personnel; Water, which tests any purified water used at any stage of the drug production process, including water for injection; In-Process Bioburden, which tests raw materials, drug substance and in-process product, and Sterility Release offering final testing of finished product to ensure sterility before the product is released for commercial sale.
The current stock price of RPID is 2.87 USD. The price decreased by -1.37% in the last trading session.
RPID does not pay a dividend.
RPID has a ChartMill Technical rating of 5 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
10 analysts have analysed RPID and the average price target is 8.16 USD. This implies a price increase of 184.32% is expected in the next year compared to the current price of 2.87.
RAPID MICRO BIOSYSTEMS INC-A (RPID) currently has 163 employees.
RAPID MICRO BIOSYSTEMS INC-A (RPID) will report earnings on 2025-11-06, before the market open.
ChartMill assigns a technical rating of 5 / 10 to RPID. When comparing the yearly performance of all stocks, RPID is one of the better performing stocks in the market, outperforming 94.28% of all stocks.
ChartMill assigns a fundamental rating of 2 / 10 to RPID. RPID may be in some trouble as it scores bad on both profitability and health.
Over the last trailing twelve months RPID reported a non-GAAP Earnings per Share(EPS) of -1.01. The EPS increased by 13.68% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -58.36% | ||
| ROE | -80.87% | ||
| Debt/Equity | 0 |
10 analysts have analysed RPID and the average price target is 8.16 USD. This implies a price increase of 184.32% is expected in the next year compared to the current price of 2.87.
For the next year, analysts expect an EPS growth of 6.97% and a revenue growth 15.94% for RPID